Mibefradil, a T-type and L-type calcium channel blocker, limits infarct size through a glibenclamide-sensitive mechanism

Cardiovascular Drugs and Therapy

Volumn 13, Issue 2, 1999, Pages 115-122

  Mocanu, Michaela M ^b   Gadgil, Shashi ^a   Yellon, Derek M ^a,c   Baxter, Gary F ^a  

^a UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^b VICTOR BABES NATIONAL INSTITUTE OF PATHOLOGY   (Romania)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Amlodipine; Chelerythrine; Glibenclamide; Infarct size; Ischemic preconditioning; K(ATP); Mibefradil; Myocardium; Protein kinase c

Indexed keywords

AMLODIPINE; CALCIUM CHANNEL BLOCKING AGENT; CHELERYTHRINE; GLIBENCLAMIDE; MIBEFRADIL; PROTEIN KINASE C INHIBITOR; TRIPHENYLTETRAZOLIUM;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DILATATION; DRUG MECHANISM; HEART INFARCTION PREVENTION; HEART INFARCTION SIZE; HEART PROTECTION; ISOLATED HEART; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REPERFUSION INJURY;

ANIMALS; BENZIMIDAZOLES; CALCIUM CHANNEL BLOCKERS; DISEASE PROGRESSION; ENZYME ACTIVATION; GLYBURIDE; HEMODYNAMIC PROCESSES; ISCHEMIC PRECONDITIONING, MYOCARDIAL; MALE; MIBEFRADIL; MYOCARDIAL INFARCTION; PROTEIN KINASE C; RATS; RATS, SPRAGUE-DAWLEY; RISK FACTORS; TETRAHYDRONAPHTHALENES;

EID: 0032906493     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1007732025184     Document Type: Article

References (21)

1. 1. Tsien RW, Fox AP, Hess P, MeCleskcy EW, Nilius R, Nowycky MC, Rosenberg RL. Multiple types of calcium channel in excitable cells. Soc Gen Physiol Ser 1987;41:167-187.
2. 2. Nayler WG. Calcium antagonists: Whither now? Cardiovasc Drugs Ther 1988;1:617-619.
3. 3. Bush LR, Romson JL, Ash JL, Lucchesi BR. Effect of diltiazem on extent of ultimate myocardial injury resulting from temporary coronary artery occlusion in dogs. J Cardiovasc Pharmacol 1982;4:285-296.
4. 4. Haga Y, Hatori N, Nordlander M, Nordlander R, Sjoquist PO, Ryden L. Coronary venous retroinfusion of felodipine reducing infaret size without affecting regional myocardial blood flow. Eur Heart J 1993;14:1386-1393.
5. 5. Garcia-Dorado D, Theroux P, Fernandez-Avilcs F, Elizaga J, Solares J, Galinanes M. Diltiazem and progression of myocardial ischemic damage during coronary artery occlusion and reperfusion in porcine hearts. J Am Coll Cardiol 1987;10:906-911.
6. 6. Hoff PT, Tamura Y, Lucchesi BR. Cardioprotective effects of amlodipine in the ischemic-reperfused heart. Am J Cardiol 1989;64:1011-1061.
7. 7. Roberts R. Review of calcium antagonist trials in acute myocardial infarction, Clin Cardiol 1989;12(Suppl. 3): III41-III47.
8. 8. Ferrari R, Visioli O. Calcium channel blockers and ischaemic heart disease: Theoretical expectations and clinical experience. Eur Heart. J 1991;12(Suppl. F):18-24.
9. 9. Landmark K, Abdelnoor M, Kilhovd B, Dorum HP. Infaret size as estimated from peak creatine kinase and lactate dehydrogenase is probably reduced in patients using calcium antagonists at the onset of symptoms. Cardiovasc Drug Ther 1997;11:557-565.
10. 10. Abernethy DR. Pharmacologie and pharmacokinetic profile of miberfradil, a T-and L-type calcium channel antagonist. Am J Cardiol 1997;80(Suppl. 4B):4C-11C.
11. 11. Vander Heide RS, Schwarts LM, Reimer KA. The novel calcium antagonist Ro 40-5967 limits myocardial infaret size in the dog. Cardiovasc Res 1994;28:1526-1532.
12. 12. Richard V, Tron C, Blanc T, Thuillez C. Infaret size limiting properties of Ro 40-5967, a novel non-dihydropyridine calcium channel blocker in anaesthetised rats: Comparisom with verapamil. J Cardiovasc Pharm 1995;25:552-557.
13. 13. Joyeux M, Baxter GF, Thomas DL, Ribuot C, Yellon DM. Protein kinase C is involved in resistance to myocardial infarction induced by heat stress. J Mol Cell Cardiol 1997;29:3311-3319.
14. 14. Bugge E, Ytrehus K. Inhibition of sodium-hydrogen ex-change reduces infaret size in the isolated rat heart - a protective additive to ischaemic preconditioning. Cardiovasc Res 1995:29:269-274.
15. 15. Roux S, Buhler M, Clozel JP. Mechanisms of the antiischemic effect of mibefradil, a selective T calcium channel blocker in dogs: Comparison with amlodipine. J Cardiovasc Pharmacol 1996;27:132-139.
16. 3H] desmethoxyverapamil receptor, is devoid of the negative inotropic effects of verapamil in normal and failing rat hearts. Cardiovasc Drug Ther 1990;4:731-736.
17. 2+ channels by Ro 40-5967. Circ Res 1994;75:144-148.
18. 18. Karila-Cohen D, Dubois-Rande JL, Giudicelli JF, Berdeaux A. Effects of mibefradil on large and small coronary arteries in conscious dogs: Role of vascular endothelium. J Cardiovasc Pharmacol 1996;28:271-277.
19. 2+ current is expressed in hypertrophied adult feline left ventricular myocytes. Circ Res 1993;73:777-782.
20. 20. Garlid KD, Paucek P, Yarov-Yarovny V, et al. Cardioprotective effect of diazoxide and its interaction with mitochondrial ATP-sensitive K channels. Possible mechanism of cardioprotection. Circ Res 1997;81:1072-1082.
21. 21. Liu Y, Sato T, O'Rourke B, Marban E. Mitochondrial ATP-dependent potassium channels: Novel effectors of cardioprotection? Circulation 1998;97:2463-2469.